Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis-Reference-Cited by-同舟云学术

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

Published:2012-03 Issue:3 Volume:11 Page:241-249
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Sperling Reisa,Salloway Stephen,Brooks David J,Tampieri Donatella,Barakos Jerome,Fox Nick C,Raskind Murray,Sabbagh Marwan,Honig Lawrence S,Porsteinsson Anton P,Lieberburg Ivan,Arrighi H Michael,Morris Kristen A,Lu Yuan,Liu Enchi,Gregg Keith M,Brashear H Robert,Kinney Gene G,Black Ronald,Grundman Michael

Publisher

Elsevier BV

Subject

Clinical Neurology

Reference27 articles.

1. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease;Salloway;Neurology,2009

2. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study;Rinne;Lancet Neurol,2010

3. A single ascending dose study of bapineuzumab in patients with Alzheimer disease;Black;Alzheimer Dis Assoc Disord,2010

4. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab;Ostrowitzki;Arch Neurol,2011

Cited by 406 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of ADNI MRI;Alzheimer's & Dementia;2024-09-11

2. Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease;CPT: Pharmacometrics & Systems Pharmacology;2024-08-29

3. Clinical and neuroimaging precursors in cerebral amyloid angiopathy: impact of the Boston criteria version 2.0;European Journal of Neurology;2024-08-06

4. Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA;2024-07-26

5. Targeting soluble amyloid-beta oligomers with a novel nanobody;Scientific Reports;2024-07-12